On June 24, the CDE official website showed that the New Drug Application (NDA) for Encorafernib Capsules, filed by Pierre Fabre, has been accepted for the first-line treatment of adult patients with BRAF V600E-mutant metastatic colorectal cancer (CRC) in combination with cetuximab and FOLFOX. This indication was granted Priority Review by the CDE in April 2026. According to the Insight database, this is the third indication for encorafenib submitted for marketing approval in China. Previously, encorafenib had been approved for two indications: in combination with cetuximab for BRAF V600E-mutant colorectal cancer, and in combination with binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.
Encorafenib is a BRAF inhibitor originally developed by Array BioPharma. In June 2019, Pfizer acquired Array for a total transaction value of $11.4 billion, gaining exclusive development and commercialization rights to the product in the United States, Canada, Latin America, Africa, and the Middle East. Ono Pharmaceutical holds development and commercialization rights in Japan and South Korea, while Pierre Fabre Laboratories holds exclusive rights in Europe, Asia, and Latin America. Encorafenib has received global approvals for multiple indications, including colorectal cancer, non-small cell lung cancer, thyroid cancer, and melanoma. According to Pfizer’s financial reports, encorafenib and binimetinib generated $716 million in sales for the company in 2025, representing an 18% year-over-year increase.
Buy BRAFTOVI®Encorafenib from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
